Evidence map›Paper›PMID 30237264›Full record

Trial reportHaematologica2018

Daratumumab plus bortezomib and dexamethasone

Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi and 27 more

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 10 pooled it
28.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 10 syntheses or guidelines pooled it, 257 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 16 countries.

Andrew SpencerMalignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia aspencer@netspace.net.au.
Suzanne LentzschDivision of Hematology/Oncology, Columbia University, New York, NY, USA.
Katja WeiselUniversitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tübingen, Germany.
Hervé Avet-LoiseauUnite de Genomique du Myelome, CHU Rangueil, Toulouse, France.
Tomer M MarkDepartment of Medicine, University of Colorado, Aurora, CO, USA.
Ivan SpickaClinical Department of Haematology, 1 Medical Department, Charles University in Prague, Czech Republic.
Tamas MassziDepartment of Haematology and Stem Cell Transplantation, St László Hospital, 3 Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
Birgitta LauriDepartment of Hematology, Sunderbyn Hospital, Luleå, Sweden.
Mark-David LevinAlbert Schweitzer Hospital Department of Internal Medicine, Dordrecht, the Netherlands.
Alberto BosiDepartment of Hematology, Careggi Hospital and University of Florence, Italy.
Vania HungriaIrmandade Da Santa Casa De Misericordia De São Paulo, Brazil.
Michele Cavo"Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
Je-Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, South Korea.
Ajay K NookaWinship Cancer Institute, Emory University, Atlanta, GA, USA.
Hang QuachSt. Vincent's Hospital, University of Melbourne, Australia.
Cindy LeeRoyal Adelaide Hospital, North Terrace, Australia.
Wolney BarretoHospital Santa Marcelina, São Paulo, Brazil.
Paolo CorradiniFondazione IRCCS Instituto Nazionale dei Tumori, University of Milan, Italy.
Chang-Ki MinSeoul St. Mary's Hospital, South Korea.
Emma C ScottOregon Health & Science University, Portland, OR, USA.
Asher A Chanan-KhanMayo Clinic Florida, Jacksonville, FL, USA.
Noemi HorvathRoyal Adelaide Hospital, North Terrace, Australia.
Marcelo CapraInstituto do Cancer-Hospital Mae de Deus, Porto Alegre, Brazil.
Meral BeksacAnkara University, Turkey.
Roberto OvillaHospital Angeles Lomas, Naucalpan de Juárez y alrededores, México.
Jae-Cheol JoUlsan University Hospital, South Korea.
Ho-Jin ShinDivision of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
Pieter SonneveldErasmus Medical Center, Rotterdam, the Netherlands.
David SoongJanssen Research & Development, LLC, Spring House, PA, USA.
Tineke CasneufJanssen Research & Development, Beerse, Belgium.
Christopher ChiuJanssen Research & Development, LLC, Spring House, PA, USA.
Himal AminJanssen Research & Development, LLC, Raritan, NJ, USA.
Ming QiJanssen Research & Development, LLC, Spring House, PA, USA.
Piruntha ThiyagarajahJanssen Research & Development, High Wycombe, UK.
A Kate SasserGenmab US, Inc, Princeton, NJ, USA.
Jordan M SchecterJanssen Research & Development, LLC, Raritan, NJ, USA.
Maria-Victoria MateosUniversity Hospital of Salamanca/IBSAL, Spain.
Janssen (United States) · USRoyal Adelaide Hospital · AUAlbert Schweitzer Ziekenhuis · NLAnkara University · TRAzienda Ospedaliero-Universitaria Careggi · ITCharles University · CZChonnam National University Hwasun Hospital · KRColumbia University · USEmory University · USErasmus MC · NLGenmab (United States) · USHôpital Rangueil · FRHospital Angeles Clinica Londres · MXHospital Mãe de Deus · BRHospital Santa Marcelina · BRInstituto de Investigación Biomédica de Salamanca · ESIrmandade da Santa Casa de Misericórdia de São Paulo · BRJacksonville College · USJanssen (Belgium) · BEJanssen (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDrug Resistance, NeoplasmFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalNeoplasm, ResidualAntibodies, MonoclonalBortezomibdaratumumabDexamethasone

Identifiers

PMID30237264
PMCPMC6269293
OpenAlexW2890161608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.